A carregar...
Quality of life in patients with advanced renal cell carcinoma treated with nivolumab versus everolimus in CheckMate 025, a randomised, phase 3 clinical trial
BACKGROUND: In the phase 3 CheckMate 025 study, previously treated patients with advanced renal cell carcinoma (aRCC) randomised to nivolumab had an overall survival (OS) benefit versus everolimus. We compared health-related quality of life (HRQoL) between treatment arms and explored the relationshi...
Na minha lista:
| Publicado no: | Lancet Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5521044/ https://ncbi.nlm.nih.gov/pubmed/27283863 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30125-5 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|